Article Details - Overview
Monographs in Renal Cell Carcinoma Vol. 3, No. 1
Release Date: December 30, 2008
Expiration Date: December 30, 2009
Publication Overview
Authors
Guru Sonpavde, MD; Robert Motzer, MD; Thomas Hutson, DO, PharmD, FACP; Thomas Powles, MD, MBBS, MRCP
Overview and Purpose
The American Cancer Society estimates that in 2008 approximately 54,000 cases of renal cell carcinoma (RCC) will be newly diagnosed, with 13,000 resultant deaths. The introduction of targeted agents, which are believed to function in metastatic RCC by suppressing the enhanced angiogenesis associated with this tumor type, has rapidly revolutionized the treatment of this historically refractory disease. Agents currently used in the clinic and those entering clinical development mainly represent the multitargeted tyrosine kinase inhibitor (TKI), monoclonal antibody (MoAb), and mammalian target of rapamycin (mTOR) inhibitor drug classes, and a number of other targets of interest are also entering development. These reviews focus on data from clinical trials of TKIs, MoAbs, and mTOR inhibitors that have demonstrated activity in patients with advanced/metastatic RCC and on potential future therapeutic strategies.
The purpose of this activity is to reinforce mechanisms of action of major drug classes currently available as therapy for patients with RCC and highlight data from phase III clinical trials in RCC and inform physicians about novel agents and combination regimens currently under clinical investigation.
Target Audience
This activity is intended for medical oncologists involved in the care of patients with renal cell carcinoma. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Compare efficacy and safety data from randomized clinical trials evaluating the role of antiangiogenic agents in the treatment of metastatic RCC
- Differentiate the toxicity profiles of novel antiangiogenic agents undergoing clinical development in phase II trials
- Assess efficacy and safety data from randomized clinical trials evaluating mTOR inhibitors in the treatment of advanced/metastatic RCC
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- Study the educational activity.
- Complete the CME test.
- Answer the evaluation questions.
- After successful completion of the CME test and evaluation, you will receive your certificate of credit online.
CME credit will be granted for only 1 form of participation, either online or via the printed publication.
You will be asked to login
or create an account.